Abstract
To construct an injectable fibrin glue system loaded with kaempferol (FG@F) to improve the bioavailability of kaempferol and observe its efficacy in the treatment of intervertebral disc degeneration (IVDD). Kaempferol-loaded fibrin glue was first synthesized in advance. Subsequently, the materials were characterized by various experimental methods. Then, nucleus pulposus cells (NPCs) were stimulated with lipopolysaccharide (LPS) to establish a degenerative cell model, and the corresponding intervention treatment was conducted to observe the effect in vitro. Finally, the tail disc of rats was punctured to establish a model of IVDD, and the therapeutic effect of the material in vivo was observed after intervertebral disc injection. The FG@F system has good injectability, sustained release and biocompatibility. This treatment reduced the inflammatory response associated with IVDD and regulated matrix synthesis and degradation. Animal experimental results showed that the FG@F system can effectively improve needle puncture-induced IVDD in rats. The FG@F system has better efficacy than kaempferol or FG alone due to its slow release and mechanical properties. The drug delivery and biotherapy platform based on this functional system might also serve as an alternative therapy for IVDD.
Similar content being viewed by others
Introduction
Intervertebral disc degeneration (IVDD) is a chronic degenerative disease1,2. IVDD is primarily caused by catabolic and anabolic disorders as well as changes in the microenvironment3. Through protection of nucleus pulposus cells (NPCs) and restoration of the IVDD microenvironment, IVDD treatment effectiveness can be increased4,5. Pyroptosis is a newly discovered inflammatory programmed cell death mode that can be triggered by the NLRP3 inflammasome and accompanied by the release of a large number of proinflammatory factors6. This process contributes to the gradual loss of extracellular matrix (ECM), leading to senescence and death of NPCs7. In addition, during IVDD, the abnormal expression of ADAMTS-5 and collagen II degradation disrupt the ECM balance by reducing the secretion of type II collagen from NPCs8,9. A cascade of exacerbated reactions occurs as a result of the remodelling of the IVDD microenvironment, as well as the accumulation of inflammatory factors and the death of NPCs. To alleviate IVDD, researchers need to restore the healthy IVDD microenvironment and protect NPCs6,10.
Kaempferol is a flavonoid that is slightly soluble in water, is soluble in organic solvents such as hot ethanol and DMSO, and has suitable anti-inflammatory and antioxidant effects11,12. Studies have shown that kaempferol exerts its anti-inflammatory effects by inhibiting the TLR4/NF-ĸB signalling pathway13. However, the role of kaempferol in IVDD and its related mechanisms are still rarely studied. Moreover, this simple drug is easily degraded when injected into the body, and it is difficult to exert lasting drug effects14,15.
Drug delivery systems are widely used in the treatment of many diseases and have the advantages of specific targeting, high biocompatibility and controlled release16. Fibrin glue (FG), a drug carrier consisting of fibrinogen solution and thrombin solution, is used for haemostasis, wound healing, and bone regeneration17. Studies have shown that FG, when used as a scaffold, can improve cell survival, proliferation, differentiation, and matrix synthesis and is a promising drug delivery system18.
This study used resurrection lily phenol for optimal disc metabolic regulation. Fibrin glue was used to assist NPCs in combating inflammation by exerting optimal therapeutic properties and biological compatibility. By combining galanga resurrection lily phenol with fibrin glue, we constructed an injectable drug fibrin glue system to effectively restore the IVDD microenvironment and protect NPCs from inflammation after IVDD. Compared with traditional scaffolds, fibrin glue uses natural biological materials, does not contain toxic crosslinking agents, and has suitable anti-inflammatory and pro-proliferative effects19,20,21. FG@F was proven to be injectable and stable in vitro, maintaining a stable elastic solid morphology at 37 °C. The drug release curve showed that the fibrin glue could sustainably release kaempferol to exert a long-lasting drug effect. In addition, fibrin glue was examined for its effects on matrix catabolism and inflammation in degenerative NPCs. By using a rat tail disc degeneration model, we confirmed that fibrin glue could alleviate ECM degradation and promote ECM regeneration (Scheme 1). This study developed a novel IVDD bioglue to modulate the microenvironment, treat IVDD, and deliver kaempferol.
Materials and methods
Synthesis of FG@F
Fibrinogen was selected from bovine fibrinogen produced by Yeasen Biotechnology Co. (China). Fibrin was dissolved using 0.9% NaCl at 35 mg/10 ml. Thrombin was purchased from Zhejiang Hangkang Pharmaceutical Co., Ltd. (5000 U). A thrombin solution of 100 U/ml was prepared using 5% CaSO4. The fibrin glue was prepared with a 1:10 thrombin:fibrinogen ratio. The drug-loaded fibrin glue was prepared by mixing kaempferol (MedChemExpress, USA) with fibrinogen at a ratio of 1:10, and then, thrombin was injected into the mixed liquid for crosslinking.
Physicochemical and multifunctional properties
Characterizations of FG@F
The porous morphology of FG@F was observed using scanning electron microscopy (SEM) (Hitachi SU8010, Japan). For determination of the rheological properties of the scaffolds (Gʹ and Gʹʹ), a rheometer (HAAKE MARS60, Germany) was employed. Using strain and frequency constants of 1% and 1 Hz, we investigated the effects of temperature on FG@F ranging from 4 to 50 °C. The injectability of biological scaffolds was determined by measuring viscosity changes with shear rate. All experiments were repeated three times.
Profile of kaempferol release from FG@F
Kaempferol release profiles were determined using Varioskan LUX (Thermo Scientific, USA). Briefly, 6 mg of kaempferol preparation was added to 3 ml of FG@F. The samples were immersed in 5 ml of PBS at 37 °C and replaced with 300 µl of fresh PBS at 12 h, 1 day, 2 days, 4 days, 8 days, and 12 days after the start of incubation. The sample absorbance was detected at 435 nm, and 6 mg kaempferol was added to 3 ml of PBS to determine the absorbance of the stock solution. Then, the absorbance value determined by the sample was compared with the absorbance of the stock solution to calculate the percentage of kaempferol release. All experiments were repeated three times.
Cytotoxicity and proliferation assays
NPCs were obtained from nucleus pulposus tissue isolated from tail discs of 4-week-old male Sprague–Dawley (SD) rats and purchased from Zhejiang Medical College (Hangzhou, China). Primary NPCs were obtained by continuous digestion with collagenase II (Solaibao, China) at 37 °C for 4 h, filtered through a sieve and centrifuged at 1000 rpm for 5 min. The isolated NPCs were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS in a humidified incubator with 5% CO2. The medium was changed every other day. In the next experiment, we used cells from the second passage. The cytotoxicity and proliferation of FG and FG@F cultured for 1, 3, and 5 days were evaluated using a CCK-8 assay kit (Boster, Wuhan, China). Absorbance was measured at 450 nm after 10 µl of CCK-8 solution was added to the NPCs using Varioskan LUX (Thermo, USA). For determination of the distribution of living cells, a Calcein/PI Cell Viability/Cytotoxicity Assay Kit (Beyotime, China) was used. For fluorescence images, NPCs were incubated with calcein-AM (1 M) for 30 min in a 37 °C incubator. All experiments were repeated three times.
Immunofluorescence
The cells were washed three times with PBS and fixed for 15 min with precooled methanol at − 20 °C. After permeabilization of the cell membranes with 0.5% Triton X-100 for 20 min, the cells were washed again with PBS 3 times. We blocked the cells with 5% BSA for 30 min, added the appropriate primary antibody to the cells and incubated them at 4 °C overnight. The primary antibody information was as follows: rabbit anti-collagen II (1:500; Proteintech), rabbit anti-ADAMTS-5 (1:500, Proteintech), rabbit anti-NLRP3 (1:500, Proteintech) and rabbit anti-IL-1β (1:500, Proteintech). After three washes with PBS, we added goat anti-rabbit Alexa Fluor 488 and 594 antibodies (Beyotime, China). After 10 min, the samples were stained with DAPI (Beyotime, China) at room temperature. The above experiments were performed three times with a fluorescence microscope (Olympus BX51, Japan) and repeated three times.
Cellular treatments and real-time PCR (qPCR)
Cells were divided into five groups: control (Con group), 24 h LPS treatment + 1 h ATP treatment (LPS group), 24 h LPS treatment + 1 h ATP treatment + kaempferol (F group), 24 h LPS treatment + 1 h ATP treatment + FG (FG group) and 24 h LPS treatment + 1 h ATP treatment + FG@F (FG@F group). Cells in the F and FG groups were pretreated with kaempferol for 2 h before the addition of 2 µg/ml LPS (MedChemExpress, USA) and 5 mM ATP (MedChemExpress, USA). We extracted RNA from lysed NPCs with TRIzol reagent (Invitrogen, USA) and an RNA Purification Kit (CW0581, Kangwei) and reverse transcribed the RNA using a strand cDNA synthesis kit (Yisheng, China).Then, cDNA was quantified by real-time PCR. GAPDH was used as an internal standard. The primers used are listed in Table 1. All experiments were repeated three times.
Western blot
The NPCs were washed 3 times with PBS and then lysed with ice-cold RIPA lysis buffer containing PMSF (1:100) (Fudebio, China). After 15 min, each well was scraped with a cell scraper, and the cell lysate was collected into an EP tube, centrifuged at 12,000 rpm, and incubated at 4 °C for 15 min to generate whole-cell extracts. The supernatants were collected. An enhanced BCA protein detection kit (Beyotime, China) was used to determine the protein concentration. A one-step adhesive (Fudebio, China) was used with 10 µl of sample and 10 µl of marker per well (Fudebio, China). Proteins were transferred to a membrane and blocked with 5% skim milk for 2 h before overnight incubation with the following primary antibodies: rabbit anti-collagen II (1:1000; ABclonal), rabbit anti-Sox9 (1:1000; ABclonal), and rabbit anti-GAPDH (1:5000; ABclonal). For removal of excess antibodies, the membrane was washed with TBST three times for 5 min before being incubated with specific horseradish peroxidase-conjugated secondary antibodies (Beyotime, China) for 1 h at room temperature. Three 5-min TBST washes were performed to remove excess secondary antibodies. The intensity of the reaction bands on the membrane was measured using the ChemiDoc Touch Imaging System (Bio-Rad, USA). The experiment was repeated in triplicate.
RNA-seq
Cells were divided into three groups: control (Con group), 24 h LPS treatment + 1 h ATP treatment (LPS group), and 24 h LPS treatment + 1 h ATP treatment + FG@F (LPS + FG@F group). We extracted RNA from lysed NPCs with TRIzol reagent (Invitrogen, USA). mRNA was purified from 1 μg of total RNA using oligo (dT) magnetic beads, and then, mRNA fragmentation was performed in ABclonal First Strand Synthesis Reaction Buffer. PCR products were purified, and library quality was assessed using an Agilent Bioanalyzer 4150. For sequencing using the NovaSeq 6000 sequencing platform PE150 for read length and the data generated from the Illumina (or BGI) platform for bioinformatics analysis, we chose HISAT2 as the mapping tool for the reference genome. The DESeq2 R package was used to analyse the differential expression between any two groups. The genes with P < 0.05 identified by DESeq2 were considered differentially expressed genes (DEGs). The differentially expressed genes were subjected to enrichment analyses by the clusterProfiler R software packages GO, KEGG and GSEA. The experiments were repeated five times.
Animal surgery
Shanghai BK Laboratory Animal Co., Ltd. (China), provided SD rats (n = 80, 180–220 g, male). The rat treatment guidelines were approved by the animal ethics committee of Zhejiang Chinese Medical University Laboratory Animal Research Center. Ketamine and xylazine were used to anaesthetize the animals (10:7100 mg/kg i.p.). IVDD was established by puncturing the coccygeal space at C5–6, C6–7, C7–8, and C9–10. After disinfection with iodoalcohol, a 26G needle (diameter = 0.45 mm) was inserted at the level of the annulus fibrosus by palpation and passed through the NP to reach the contralateral annulus fibrosus. After incomplete penetration, the needle was rotated 360° twice for 30 s. All experiments were conducted under sterile conditions. One week after the initial puncture, each group of rats was injected with a 26G needle for treatment. The experiment consisted of 5 groups (n = 8): (1) NC group (no puncture); (2) DC group (puncture and injection of 5 µl of PBS); (3) kaempferol group (puncture and injection of 5 µl of kaempferol); (4) FG group (puncture and injection of 5 µl of FG); (5) FG@F group (puncture and injection of 5 µl of FG@F). Rats were subjected to further assessments at 4 and 8 weeks after treatment. All animal experiments were performed in accordance with the ARRIVE guidelines and regulations.
Radiological assessment analysis
MicroCT (SkyScan, Belgium) and MRI (Universal Corporation, USA) were performed at 4 weeks and 8 weeks, respectively, to evaluate the signal intensity of the nucleus pulposus and the height of the vertebral space. The T2-weighted signal intensity of the nucleus pulposus of each disc was quantified in MRI images using ImageJ software. MRI images were classified into grades I to IV (I, normal; II, slightly decreased signal intensity but significantly narrowed hyperintense area; III, moderately decreased signal intensity; and IV, severely decreased signal intensity). The disc height of each rat was measured in the CT images using ImageJ (National Institutes of Health, USA).
Histological and immunohistochemical analyses of IVDD model rats
The rats in each group were overdosed with carbon dioxide at week 4 and week 8. The corresponding disc segment was removed, and the sample was temporarily fixed in 10% neutral buffered formalin. The skin and muscle tissue were removed by dissection, and the sample was then immersed in a decalcified solution (10% EDTA) for 4 weeks. Histological section (8 μm) were prepared using a microtome. H&E staining and Safranin O-fast green (SO) staining were used to assess the extent of IVDD in each group. Two blinded observers assessed the number and morphology of the cells. The grading method was based on a previously reported method22. Collagen II was used as an immunohistochemical indicator to assess the degree of disc degeneration. The sample was treated with hydrogen peroxide (3%) for 10 min. The sample was then sealed with 5% BSA at room temperature for half an hour and treated with a mouse anti-rabbit collagen II antibody (1:100; Proteintech) at 4 °C overnight. After 5 washes with PBS, the samples were incubated with biotin-labelled secondary antibodies at 37 °C for 30 min. The staining was developed using the SABC method.
Statistical analysis
The two groups of data were compared with an independent sample t test, and comparisons of multiple sets of data were performed using one-way ANOVA. All data are expressed as the mean ± standard deviation (SD). P < 0.05 was considered to indicate statistical significance. All intensity signal fluxes and fluorescence expression were calculated using ImageJ software (San Diego, CA, USA). The column graphs were drawn using GraphPad Prism 9 software.
Ethics approval and consent to participate
The Committee for Zhejiang Chinese Medical University Laboratory Animal Research Center authorised all animal experiments following a robust ethical review.
Results
Preparation and characterization of FG@F
We succeeded in preparing FG and FG@F. The molecular structure of kaempferol is shown in Fig. 1H. After the samples were freeze dried under a scanning electron microscope (SEM), FG and FG@F were observed (Fig. 1A). Surprisingly, we found that compared with FG, FG@F had greater stability, and after 2 weeks in vitro, FG@F still maintained suitable stability (Fig. 1D). Atomic force microscopy (AFM) showed that compared with FG, FG@F had a rougher surface (Fig. 1E), which verified kaempferol particle adhesion to the FG surface. The molecular structure diagram of kaempferol is shown (Fig. 1F). In addition, the zeta potential of kaempferol was − 25.4 mV (Fig. 1C), and since the surface of FG carries a large number of positively charged groups, kaempferol can strongly bind to it.
Evaluation of the properties of FG@F
The rheological properties of FG@F were measured to evaluate its mechanical properties. At 37 °C, FG@F showed a Gʹ value higher than Gʹʹ, indicating that it can maintain suitable viscosity in the body (Fig. 1I). As the shear rate gradually increased, the FG@F viscosity continuously decreased, showing that this system had acceptable injection performance (Fig. 1G,H). The slow release curve of FG@F confirmed that it has an excellent ability to slow-release resurrection lily phenol. Within 12 days, FG@F gradually released most of the kaempferol (Fig. 1B).
Biocompatibility of FG@F in vitro
As shown in Fig. 2D, cell viability was determined by CCK-8 assays, and kaempferol had no obvious cytotoxicity when the concentration was less than 100 µmol/l. Finally, we selected 25 µmol/l as the cell intervention concentration. In the same way, we found that at a fixed concentration of kaempferol, there was no obvious cytotoxicity when the FG@F concentration was less than 3.5 mg/ml, and finally, we chose this concentration as the cellular intervention concentration (Fig. 2E). Immunofluorescence showed that NPC quantity increased with time, and the number of NPCs was significantly higher in the FG@F group than in the NC group (Fig. 2A). The CCK-8 test showed that on the third and fifth days, the cell number was obviously increased in the FG@F group compared with the NC group, and the difference was significant (Fig. 2B). Immunofluorescence showed that there were no significant effects on cell proliferation on Days 1, 3 and 5, indicating that FG@F has good biocompatibility and that FG is an ideal carrier for kaempferol. Over time, the number of NPCs also significantly increased (Fig. 2C).
The function of FG@F in ECM metabolism
To evaluate the effect of FG@F on ECM regulation, we first used RT-qPCR to measure the expression of genes associated with ECM synthesis and degradation in the NPCs of the LPS-treated rats. Compared with the NC group, the LPS group showed decreased expression levels of collagen II in NPCs (Fig. 3D). An important factor promoting intervertebral disc degeneration is the special metalloproteinase gene ADAMTS-5. We observed that the level of ADAMTS-5 in the FG@F group was decreased compared to that in the LPS group (Fig. 3C). The results confirmed that FG@F can affect the metabolism of the ECM to regulate changes in the early disc microenvironment. WB results showed that compared to the LPS treatment, FG@F upregulated the expression of SOX9 and collagen II, affecting the metabolism of ECM (Fig. 3E–G). In addition, the immunofluorescence results showed that FG@F cleaved ADAMTS-5 and increased collagen II levels to promote NPC synthesis in the ECM, leading to ECM accumulation (Fig. 3A,B).
FG@F inhibits the inflammation of NPCs
Using NLRP3 and IL-1β immunofluorescence analysis, we found that the fluorescence intensity after FG@F treatment significantly decreased, and FG@F reduced the inflammation of NPCs (Fig. 4A,B). In addition, we assessed inflammation in NPCs by RT-qPCR. Compared with those in the NC group, the mRNA expression levels of NLRP3 and IL-1β in the LPS group were increased. However, in the FG@F group, the expression levels of NLRP3 and IL-1β decreased (Fig. 4C,D).
RNA-seq results
The difference heatmap showed that the LPS + FG@F group and LPS group had significant differences (Fig. 5A). KEGG enrichment analysis of differentially expressed genes between the LPS + FG@F group and the LPS group was performed. The results showed that FG@F can extensively inhibit inflammation-related signalling pathways: the PI3K-Akt signalling pathway, NF-kappa B signalling pathway, MAPK signalling pathway, IL-17 signalling pathway and other signalling pathways (Fig. 5B). GO enrichment analysis of differentially expressed genes was performed in the LPS + FG@F group and LPS group. The results showed biological enrichment in cell chemotaxis, leukocyte migration cell-substrate, and adhesion myeloid leukocyte migration. Cell fractions were enriched in receptor complex synaptic and membrane microdomains. The enriched molecular functions were cytokine activity, glycosaminoglycan binding, heparin binding growth factor activity, sulphur compound binding and adhesion molecule binding (Fig. 5C). The results showed that FG@F could effectively inhibit the expression of IL-1β (Fig. 5F); the addition of FG@F inhibited ADAMTS-5, a gene related to ECM metabolism, and restored the expression of collagen II, a gene related to ECM synthesis (Fig. 5D,E); GSEA showed that FG@F inhibited the inflammatory response (Fig. 5G).
Imaging evaluation of disc height
To explore the repair effect of FG@F on IVDD in rats, we established a model based on needle punctures in the coccyx discs (Fig. 6A). Then, the drug was injected into the intervertebral disc. Each group showed a certain change in disc height over time based on the X-ray analysis (Fig. 6B). The disc height index was measured in CT images using Data Viewer software (Fig. 6C). The disc height index (DHI%) significantly decreased over time in the DC group (Fig. 6D). At different time points, the DHI% of the DC group decreased significantly, and the DHI% of the F and FG groups also decreased to different degrees. The FG@F group, by contrast, showed some disc compression, but compared with the DC, F and FG groups, it still maintained a suitable intervertebral disc height (Fig. 6E,F). As shown by nuclear magnetic resonance (MRI) at 4 and 8 weeks after gavage (Fig. 6G), the NC rats presented a higher T2-weighted signal, indicating increased water content. Significant nucleus pulposus degeneration was observed in the DC group compared with the NC group (P < 0.05), and the intensity of the nucleus pulposus signal in the F, FG and FG@F groups was improved to different degrees compared with that in the DC group (P < 0.05) (Fig. 6H). Therefore, according to the results of the study, the degree of degeneration of the nucleus pulposus was reduced after treatment, which was conducive to the maintenance of vertebral space height.
Histological and immunohistochemical analyses of the IVDD model rats
According to the H&E and SO staining results, the NC group maintained complete intervertebral disc morphology, including intact nucleus pulposus tissue and a well-organized AF. Eventually, the DC group showed marked degeneration, resulting in complete fusion. In the F and FG groups, the intervertebral disc degeneration was partially repaired. The FG@F group showed an improved intervertebral structure and form compared with the DC, F and FG groups (Fig. 7A,B). Immunohistochemistry analysis showed that the expression levels of collagen II, ADAMTS-5 and IL-1β in the FG@F group were similar to those in the NC group (P < 0.05), which confirmed the ability of FG@F to improve IVDD (Fig. 7F–K). Histological scoring was performed at weeks 4 and 8 as shown (Fig. 7C–E). The DC group scored the highest, with the most serious degeneration, and the FG@F score was similar to that in the NC group (P < 0.05). This finding shows that FG@F has an optimal effect at 4 weeks, and this effect was maintained for 8 weeks.
Discussion
In this study, kaempferol-loaded fibrin glue was fabricated to modulate the IVDD microenvironment. The combination of FG and kaempferol in FG@F was more effective than traditional biological scaffolds and is more suitable for the intervertebral disc microenvironment. FG@F can slow the catabolism of ECM by reducing the activity of matrix metalloproteinases. During disc degeneration, slowing the catabolism of ECM corrects the metabolic disorder of ECM and facilitates NPC survival23,24,25. Moreover, the FG@F degradation rate was decreased, and the treatment effect could be prolonged to 12 days. In addition, kaempferol stored in FG@F inhibited the release of inflammatory factors and inactivated the NLRP3 inflammasome. Inhibition of inflammatory cytokines can affect the survival of NPCs.
The disc consists of the nucleus pulposus, annulus fibrosus, and cartilaginous endplate26. The function of the intervertebral disc is to provide stability and flexibility to the spine27,28. However, IVDD is considered to be an irreversible process in the presence of decreased cell viability, reduced proteoglycan and type II collagen synthesis, and dehydration of the nucleus pulposus29,30. FG and kaempferol act together to enhance the tolerance of NPCs to changes in the early inflammatory microenvironment of IVDD and promote their proliferation to a certain extent.
FG@F in this study showed suitable biocompatibility, with treated NPCs showing increased proliferation after 1, 3, and 5 days. Our results show that FG@F can offset the negative impact of substrate metabolic disorder caused by matrix loss and ADAMTS-5 expression. In addition, FG maintained the ECM’s original structure, improved its structural support, and promoted NPC proliferation while resisting inflammatory effects. Most importantly, FG@F can effectively slow the release of kaempferol.
The literature has confirmed that FG contains a large number of positively charged groups31. The zeta potential of kaempferol confirmed that it carries a negative charge. By electrostatic attraction, FG can effectively bind kaempferol and promote kaempferol loading.
To further explore the role of FG@F in IVDD, we performed transcriptomic analysis. Our experimental results verified that FG@F showed a good inhibitory effect on inflammation via the NF-kappa B signalling pathway, neuroactive ligand–receptor interaction, MAPK signalling pathway, and TNF-α signalling The inhibition of these pathways and other signalling pathways improved the LPS-induced inflammatory environment. In addition, previous studies have shown that anti-inflammatory therapy is an effective treatment for IVDD because cytokines do not degrade IVD directly, as MMPS or ADAMTS do, but accelerate IVD degeneration by promoting the production of inflammatory substances by disc cells28. Our results confirm that FG@F, in addition to its anti-inflammatory effects, can restore ECM synthesis and decomposition balance. Therefore, FG@F may reduce the expression of IL-1β by inhibiting NLRP3, reduce the pyroptosis of NPCs, restore the balance of ECM synthesis and decomposition, and thus alleviate IVDD.
Our results show that FG@F at 5–40 °C can maintain a stable elastic solid form. Premixing kaempferol with fibrin can result in a uniform distribution of the drug, and FG@F after injection of a high modulus allows kaempferol to be fixed in the FG.
FG, as a natural polymer material, is a new treatment material in the field of intervertebral disc degeneration. Previous studies have found that the presence of FG has a positive effect on the expression of collagen II and polymeroglycan, thus contributing to the survival and proliferation of chondrocytes32,33,34. In addition, FG has anti-inflammatory cytokines, which can enhance the anti-inflammatory effect35,36. Kaempferol is a widely used flavonoid with optimal anti-inflammatory effects and can promote the proliferation of NPCs5. Additionally, its ability to promote the proliferation and growth of NPCs and regulate ECM metabolism was further enhanced by the combination of the two. We found that their combination effectively inhibits disc degeneration, while kaempferol and FG injections alone have limited therapeutic effects.
Compared with that of cell therapy, the immunogenicity of kaempferol and FG is very low, which is the strength of clinical application of FG@F5,37. To achieve biocompatibility, we chose biological substances with low rejection rates by the body. Kaempferol is a safe drug approved for the market. Fibrinogen and thrombin are widely available, and if the human body is exposed to them, their harm to the human body is negligible. The FG@F crosslinking process using thrombin is safe. The amount of thrombin is only approximately 1/10 of the prepared solution, and thrombin showed no significant cytotoxicity to NPCs. Our final goal is to develop drug-loaded glues for IVDD treatment.
Nevertheless, this study still has some limitations. We were not able to determine the exact mechanism by which FG@F inhibits NLRP3 aggregation and exerts its anti-inflammatory effects. The specific molecular mechanism by which FG@F delays IVDD deserves further exploration.
Conclusions
In this study, a new type of kaempferol-loaded fibrin glue was developed with good mechanical strength, sustained release, and low toxicity. Kaempferol loaded into fibrin glue provides a continuous anti-inflammatory effect by inhibiting the aggregation of NLRP3, regulating the ECM metabolism of NPCs, and repairing IVDD. Therefore, FG@F may be a new strategy for IVDD biological therapy.
Data availability
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
References
Hoy, D. et al. The global burden of low back pain: Estimates from the global burden of disease 2010 study. Ann. Rheum. Dis. 73(6), 968–974 (2014).
Francisco, V. et al. A new immunometabolic perspective of intervertebral disc degeneration. Nat. Rev. Rheumatol. 18(1), 47–60 (2022).
Binch, A. L. A. et al. Cell-based strategies for IVDD repair: Clinical progress and translational obstacles. Nat. Rev. Rheumatol. 17(3), 158–175 (2021).
Bermudez-Lekerika, P. et al. Immuno-modulatory effects of intervertebral disc cells. Front. Cell Dev. Biol. 10, 924692 (2022).
Zhu, J. et al. Kaempferol slows intervertebral disc degeneration by modifying lps-induced osteogenesis/adipogenesis imbalance and inflammation response in bmscs. Int. Immunopharmacol. 43, 236–242 (2017).
Chao-Yang, G., Peng, C. & Hai-Hong, Z. Roles of nlrp3 inflammasome in intervertebral disc degeneration. Osteoarthr. Cartil. 29(6), 793–801 (2021).
Ohnishi, T., Iwasaki, N. & Sudo, H. Causes of and molecular targets for the treatment of intervertebral disc degeneration: A review. Cells 11(3), 394 (2022).
Le Maitre, C. L. et al. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem. Soc. Trans. 35(Pt 4), 652–655 (2007).
Malemud, C. J. Inhibition of mmps and adam/adamts. Biochem. Pharmacol. 165, 33–40 (2019).
Xing, H. et al. Injectable exosome-functionalized extracellular matrix glue for metabolism balance and pyroptosis regulation in intervertebral disc degeneration. J. Nanobiotechnol. 19(1), 264 (2021).
Alam, W. et al. Kaempferol as a dietary anti-inflammatory agent: Current therapeutic standing. Molecules 25(18), 4073 (2020).
Periferakis, A. et al. Kaempferol: Antimicrobial properties, sources, clinical, and traditional applications. Int. J. Mol. Sci. 23(23), 15054 (2022).
Chang, S. et al. Kaempferol exerts a neuroprotective effect to reduce neuropathic pain through tlr4/nf-ĸb signaling pathway. Phytother. Res. 36(4), 1678–1691 (2022).
McKenzie, M. et al. Glue-based drug delivery systems for poorly water-soluble drugs. Molecules 20(11), 20397–20408 (2015).
Bamrungsap, S. et al. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine 7(8), 1253–1271 (2012).
Vashist, A. et al. Recent advances in glue based drug delivery systems for the human body. J. Mater. Chem. B 2(2), 147–166 (2014).
Spicer, P. P. & Mikos, A. G. Fibrin glue as a drug delivery system. J. Control Release 148(1), 49–55 (2010).
Kim, Y. S. et al. Mesenchymal stem cell implantation in osteoarthritic knees: Is fibrin glue effective as a scaffold? Am. J. Sports Med. 43(1), 176–185 (2015).
Buchaim, D. V. et al. Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: A systematic review. J. Venom. Anim. Toxins Include. Trop. Dis. 25, 38 (2019).
Kızıltoprak, M. & Uslu, M. Comparison of the effects of injectable platelet-rich fibrin and autologous fibrin glue applications on palatal wound healing: A randomized controlled clinical trial. Clin. Oral Investig. 24(12), 4549–4561 (2020).
Ortiz, A. C. et al. Effects of therapy with fibrin glue combined with mesenchymal stem cells (mscs) on bone regeneration: A systematic review. Cells 10(9), 2323 (2021).
Han, B. et al. A simple disc degeneration model induced by percutaneous needle puncture in the rat tail. Spine 33, 1925–1934 (2008).
Zhang, S. et al. Extracellular matrix in intervertebral disc: Basic and translational implications. Cell Tissue Res. 390(1), 1–22 (2022).
Liang, H. et al. The proteolysis of ecm in intervertebral disc degeneration. Int. J. Mol. Sci. 23(3), 1715 (2022).
Roberts, S. et al. Histology and pathology of the human intervertebral disc. JBJS 88, 10–14 (2006).
Desmoulin, G. T., Pradhan, V. & Milner, T. E. Mechanical aspects of intervertebral disc injury and implications on biomechanics. Spine 45(8), E457–E464 (2020).
Ashinsky, B. et al. Intervertebral disc degeneration and regeneration: A motion segment perspective. Eur. Cell Mater. 41, 370–380 (2021).
Kepler, C. K. et al. The molecular basis of intervertebral disc degeneration. Spine J. 13(3), 318–330 (2013).
Wang, W. J. et al. Mmps and adamtss in intervertebral disc degeneration. Clin. Chim. Acta 448, 238–246 (2015).
Tsingas, M. et al. Sox9 deletion causes severe intervertebral disc degeneration characterized by apoptosis, matrix remodeling, and compartment-specific transcriptomic changes. Matrix Biol. 94, 110–133 (2020).
Koopman, J. E. et al. A systematic review and meta-analysis on the use of fibrin glue in peripheral nerve repair: Can we just glue it? J. Plast. Reconstr. Aesthet. Surg. 75(3), 1018–1033 (2022).
Almqvist, K. F. et al. Culture of chondrocytes in alginate surrounded by fibrin gel: Characteristics of the cells over a period of eight weeks. Ann. Rheum. Dis. 60(8), 781–790 (2001).
Scotti, C. et al. Effect of in vitro culture on a chondrocyte-fibrin glue for cartilage repair. Knee Surg. Sports Traumatol. Arthrosc. 18(10), 1400–1406 (2010).
Peretti, G. M. et al. Review of injectable cartilage engineering using fibrin gel in mice and swine models. Tissue Eng. 12(5), 1151–1168 (2006).
Hsieh, J. Y. et al. Differential regulation of macrophage inflammatory activation by fibrin and fibrinogen. Acta Biomater. 47, 14–24 (2017).
Tanaka, R. et al. Preparation of fibrin glues to promote the recruitment of anti-inflammatory macrophages. Acta Biomater. 89, 152–165 (2019).
Park, C. H. & Woo, K. M. Fibrin-based biomaterial applications in tissue engineering and regenerative medicine. Adv. Exp. Med. Biol. 1064, 253–261 (2018).
Funding
This work were financially supported by The Project of Zhejiang provincial plan for TCM science and technology (2022ZB238, 2023ZR111).
Author information
Authors and Affiliations
Contributions
W.G.: Conceptualization, formal analysis, investigation, methodology, validation, writing, review and editing. J.B.: Formal analysis, investigation, methodology, validation, writing of the original draft. Y.Z.: Data curation, writing, review and editing. D.H.: Data curation, software, validation. L.Z.: Data curation. J.Z.: Data analysis. H.P.: participated in the conceptual design, formal review and supervision of the articles. D.W.: Supervision, methodology, and writing, review and editing.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gao, W., Bao, J., Zhang, Y. et al. Injectable kaempferol-loaded fibrin glue regulates the metabolic balance and inhibits inflammation in intervertebral disc degeneration. Sci Rep 13, 20001 (2023). https://doi.org/10.1038/s41598-023-47375-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-023-47375-3
- Springer Nature Limited